Cilomilast

Cilomilast

Cilomilast is a selective PDE4 inhibitor developed for treating respiratory diseases such as COPD and asthma. It was developed by GlaxoSmithKline (GSK) and first approved in the United States by the FDA in 2004.

Mechanism of Action

Cilomilast works by inhibiting the action of phosphodiesterase 4 (PDE4), an enzyme that breaks down cyclic adenosine monophosphate (cAMP). By preventing the breakdown of cAMP, Cilomilast helps to reduce inflammation and relax the muscles of the airways, thereby improving breathing in patients with respiratory diseases.

Clinical Use

Cilomilast is used primarily in the treatment of COPD, a progressive disease that makes it hard to breathe. It can also be used in the treatment of asthma, although it is not a first-line treatment for this condition. The drug is taken orally, usually once or twice a day.

Side Effects

Like all medications, Cilomilast can cause side effects. The most common side effects include nausea, diarrhea, and headache. In rare cases, it can cause more serious side effects such as weight loss, insomnia, and depression.

Development and Approval

Cilomilast was developed by GSK and first approved by the FDA in 2004. It is marketed under the brand name Ariflo. Despite its approval, the drug has not been widely used due to its side effects and the availability of other, more effective treatments for COPD and asthma.

See Also

• Phosphodiesterase 4
• Chronic obstructive pulmonary disease
• Asthma
• GlaxoSmithKline

This article is a stub related to pharmacology. You can help WikiMD by expanding it!